ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0737

Rheumatologic Rashes in Different Skin Types and Confidence in Diagnosis Among Internal Medicine Residents in a New York City Hospital
Abstract Number: 1255

Rheumatologists Overcall Sacroiliitis on X-ray and MRI in Axial Spondyloarthritis Patients: Data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT (Be-GIANT)
Abstract Number: 0239

Rheumatology Fellowship Programs – What Are Our Missions and What Are We Missing? A Mixed Methods Analysis of Publically-Available Mission Statements from the 126 Adult Rheumatology Fellowships in the United States
Abstract Number: 2173

Rheumatology Telemedicine Consults: Impact of Demographic Variability on Patient Perception in Systemic Sclerosis versus Rheumatoid Arthritis Pts
Abstract Number: 0232

RheumMadness: Early Learner Experience and Impact
Abstract Number: 1981

Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment
Abstract Number: 0308

Risankizumab (RZB) Demonstrates Long-Term Efficacy Across Subgroups in Patients with Active Psoriatic Arthritis (PsA): A Post Hoc, Integrated Analysis from the Phase 3 (KEEPsAKE 1 and KEEPsAKE 2) Studies
Abstract Number: 0710

Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Abstract Number: 1469

Risk Factors for Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1524

Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Abstract Number: 1207

Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Abstract Number: 1331

Risk Factors for Osteoporotic Fracture in Women with Established Long-Term Rheumatoid Arthritis
Abstract Number: 2196

Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Abstract Number: 0494

Risk for Visual Loss in Patients with Giant Cell Arteritis
Abstract Number: 0898

Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].